Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer

Published:2020-03 Issue:4 Volume:106 Page:733-742
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Fenwick John D.,Landau David B.,Baker Angela T.,Bates Andrew T.,Eswar Chinnamani,Garcia-Alonso Angel,Harden Susan V.,Illsley Marianne C.,Laurence Virginia,Malik Zafar,Mayles William Philip M.,Miles Elizabeth,Mohammed Nazia,Spicer James,Wells Paula,Vivekanandan Sindu,Mullin Anne-Marie,Hughes Laura,Farrelly Laura,Ngai Yenting,Counsell Nicholas

Funder

Cancer Research UK

University College London

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference27 articles.

1. Dose escalation for non-small cell lung cancer: Analysis and modeling of published literature;Partridge;Radiother Oncol,2011

2. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J Clin Oncol,2010

3. Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: Meta-analysis of randomized trials;Ramroth;Int J Radiat Oncol Biol Phys,2016

4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

5. AAPM Report 85: Tissue Inhomogeneity Corrections for Megavoltage Photon Beams;Papanikolaou,2004

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daily CBCT-based dose calculations for enhancing the safety of dose-escalation in lung cancer radiotherapy;Radiotherapy and Oncology;2024-11

2. Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers;Current Oncology;2024-03-20

3. Early Non-small Cell Lung Cancer: The Place of Radical Non-SABR Radiation Therapy;Medical Radiology;2023

4. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study;Clinical and Translational Radiation Oncology;2022-11

5. Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters;Journal of Thoracic Oncology;2022-04